• Promising data from ACCENT trial, including 5 Complete Responses and 36% Objective Response Rate
• Large-scale production of 13 kg of narmafotinib completed to GMP standards
• Preclinical data on combining narmafotinib with kRAS inhibitors presented

Amplia Therapeutics reports significant progress in the development of its best-in-class FAK inhibitor, narmafotinib, for the treatment of metastatic pancreatic cancer. The company reported mature results from the ACCENT clinical trial, which combines narmafotinib with the chemotherapies gemcitabine and Abraxane. The data analysis demonstrated a median overall survival of 11.1 months, more than two months improved over chemotherapy alone, and an unprecedented five confirmed complete responses. The updated Objective Response Rate is 35.9%. Narmafotinib is also well-tolerated by patients. Amplia presented these data at the American Association of Cancer Research annual meeting. The company's second clinical trial, AMPLICITY, is exploring the combination of narmafotinib with the chemotherapy regimen FOLFIRINOX, but recruitment has been discontinued due to dose-limiting toxicity. On the regulatory and manufacturing front, Amplia completed large-scale production of 13 kg of narmafotinib meeting GMP standards, a major milestone toward Phase 3 readiness. The company also presented new preclinical data showing that narmafotinib boosts the effectiveness of kRAS inhibitors in cancer models. Operationally, Amplia appointed a new Chief Financial Officer, Mr Hamish George.

The company reported a cash position of $27.9 million as of 31 March 2026, with net operating cash outflows of $3.5 million for the quarter.

The ACCENT and AMPLICITY trials are ongoing, and Amplia is planning new clinical studies with narmafotinib, including a registration-enabling study in combination with gemcitabine and Abraxane. Business development activities are also progressing in light of the promising ACCENT study data.